Zhuhai United Laboratories and Livzon Pharmaceutical Group are listed among the Top 100 Chinese Pharmaceutical Enterprises as the city cultivates a 100-billion-yuan ($15-billion) biomedicine industrial cluster.

This was announced at 37th China Pharmaceutical Industry Information Annual Conference, which runs Aug 30 to Sept 2 at the Zhuhai International Convention & Exhibition Center in Shizimen. On opening day, Zhuhai Party Chief Guo Yonghang spoke about the city's steps to build the cluster and become an innovation-oriented biomedicine highland with wide-reaching influence.

37th China Pharmaceutical Industry Information Annual Conference [Photo by Cheng Lin / Guanhai App]

Zhuhai United Laboratories, rated 21st nationwide, is the largest antibiotics and insulin production base in South China. Both the quality and sales of its amoxicillin and ampicillin rank first in the country. To date, 30 core products of the company have been recognized as being at a hi-tech level.

Livzon Pharmaceutical Group, rated 30th, is a comprehensive enterprise engaged in pharmaceutical R&D, production, and sales. It boasts three national and four provincial R&D platforms. As of 2019, all 31 production lines of its four pharmaceutical preparation production subsidiaries had earned Good Manufacturing Practice (GMP) certification, and 15 active pharmaceutical ingredient (API) varieties had passed on-site inspections and obtained 20 certificates issued by international certification bodies.

Both Livzon and United Laboratories are in Jinwan District.

He Wei, vice president of the Chinese People's Political Consultative Conference, delivered a video message at the opening ceremony. He urged the conference attendees to plot the goals, key tasks, and implementation of the pharmaceutical industry during the 14th Five-Year Plan (2021-25).

Both he and Wang Jiangping, deputy head of the Ministry of Industry & Information Technology, said that China should accelerate innovation-driven development and improve emergency and important drug supplies based on the successful experience of COVID-19 epidemic prevention and control.

In addition, Wang proposed the intensive and scaled production of generic drugs, integrating APIs into significant industrial clusters and backbone enterprises, and digitalizing pharmaceutical enterprises.

Scheduled for the conference are 25 activities to discuss innovation and new development trends in the industry.